5q- syndrome

Current Pharmaceutical Design

Volumn 18, Issue 22, 2012, Pages 3180-3183

  Boultwood, Jacqueline ^a   Pellagatti, Andrea ^a   Wainscoat, James S ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

Author keywords

5q syndrome; Haploinsufficiency; Myelodysplastic syndromes; p53; RPS14

Indexed keywords

ADAPTOR PROTEIN; BMI1 PROTEIN; CD34 ANTIGEN; CSNK1A1 PROTEIN; LEUCINE; MICRORNA 145; MICRORNA 146A; NUCLEOPHOSMIN; OSTEONECTIN; PROTEIN; PROTEIN P53; RIBOSOME PROTEIN; RIBOSOME PROTEIN S14; RMB22 PROTEIN; SPAG6 PROTEIN; TOLL INTERLEUKIN 1 RECEPTOR DOMAIN CONTAINING ADAPTOR PROTEIN; TRANSCRIPTION FACTOR FLI 1; TUMOR NECROSIS FACTOR RECEPTOR ASSOCIATED FACTOR 6; UNCLASSIFIED DRUG; WIG 1 PROTEIN;

5Q- SYNDROME; ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; BLACKFAN DIAMOND ANEMIA; BONE MARROW CELL; CHROMOSOME 5; CHROMOSOME DELETION; DISEASE COURSE; ERYTHROID PRECURSOR CELL; GENE ACTIVATION; GENE DELETION; GENE DOSAGE; GENE EXPRESSION; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOMIC INSTABILITY; HAPLOINSUFFICIENCY; HUMAN; MANDIBULOFACIAL DYSOSTOSIS; MYELODYSPLASTIC SYNDROME; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIORITY JOURNAL; THROMBOCYTOSIS;

EID: 84862528639     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/1381612811209023180     Document Type: Article

References (39)

1. Van den Berghe H, Cassiman JJ, David G, et al. Distinct haematological disorder with deletion of long arm of no. 5 chromosome. Nature 1974; 251: 437-8.
2. Patnaik MM, Lasho TL, Finke CM, et al. WHO-defined 'myelodysplastic syndrome with isolated del(5q)' in 88 consecutive patients: survival data, leukemic transformation rates and prevalence of JAK2, MPL and IDH mutations. Leukemia 2010; 24: 1283-9.
3. Nimer SD, Golde DW. The 5q- abnormality. Blood 1987; 70: 1705-12.
4. Boultwood J, Lewis S, Wainscoat JS. The 5q-syndrome. Blood 1994; 84: 3253-60.
5. Giagounidis AA, Germing U, Wainscoat JS, Boultwood J, Aul C. The 5q- syndrome. Hematology 2004; 9: 271-7.
6. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002; 100: 2292-302.
7. Wang L, Fidler C, Nadig N, et al. Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays. Haematologica 2008; 93: 994-1000.
8. Jaju RJ, Boultwood J, Oliver FJ, et al. Molecular cytogenetic delineation of the critical deleted region in the 5q- syndrome. Genes Chromosomes Cancer 1998; 22: 251-6.
9. Boultwood J, Fidler C, Strickson AJ, et al. Narrowing and genomic annotation of the commonly deleted region of the 5q- syndrome. Blood 2002; 99: 4638-41.
10. Boultwood J, Fidler C, Lewis S, et al. Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5qsyndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. Genomics 1994; 19: 425-32.
11. Boultwood J, Pellagatti A, Cattan H, et al. Gene expression profiling of CD34+ cells in patients with the 5q- syndrome. Br J Haematol 2007; 139: 578-89.
12. Largaespada DA. Haploinsufficiency for tumor suppression: the hazards of being single and living a long time. J Exp Med 2001; 193: F15-8.
13. Ebert BL. Deletion 5q in myelodysplastic syndrome: a paradigm for the study of hemizygous deletions in cancer. Leukemia 2009; 23: 1252-6.
14. Santarosa M, Ashworth A. Haploinsufficiency for tumour suppressor genes: when you don't need to go all the way. Biochim Biophys Acta 2004; 1654: 105-22.
15. Pellagatti A, Hellstrom-Lindberg E, Giagounidis A, et al. Haploinsufficiency of RPS14 in 5q- syndrome is associated with deregulation of ribosomal- and translation-related genes. Br J Haematol 2008; 142: 57-64.
16. Boultwood J, Pellagatti A, McKenzie AN, Wainscoat JS. Advances in the 5q- syndrome. Blood 2010; 116: 5803-11.
17. Barlow JL, Drynan LF, Hewett DR, et al. A p53-dependent mechanism underlies macrocytic anemia in a mouse model of human 5qsyndrome. Nat Med 2010; 16: 59-66.
18. Ebert BL, Pretz J, Bosco J, et al. Identification of RPS14 as a 5qsyndrome gene by RNA interference screen. Nature 2008; 451: 335-9.
19. Lipton JM, Atsidaftos E, Zyskind I, Vlachos A. Improving clinical care and elucidating the pathophysiology of Diamond Blackfan anemia: an update from the Diamond Blackfan Anemia Registry. Pediatr Blood Cancer 2006; 46: 558-64.
20. Flygare J, Karlsson S. Diamond-Blackfan anemia: erythropoiesis lost in translation. Blood 2007; 109: 3152-4.
21. Doherty L, Sheen MR, Vlachos A, et al. Ribosomal protein genes RPS10 and RPS26 are commonly mutated in Diamond-Blackfan anemia. Am J Hum Genet 2010; 86: 222-8.
22. Narla A, Ebert BL. Ribosomopathies: human disorders of ribosome dysfunction. Blood 2010; 115: 3196-205.
23. Jones NC, Lynn ML, Gaudenz K, et al. Prevention of the neurocristopathy Treacher Collins syndrome through inhibition of p53 function. Nat Med 2008; 14: 125-33.
24. McGowan KA, Li JZ, Park CY, et al. Ribosomal mutations cause p53-mediated dark skin and pleiotropic effects. Nat Genet 2008; 40: 963-70.
25. Danilova N, Sakamoto KM, Lin S. Ribosomal protein S19 deficiency in zebrafish leads to developmental abnormalities and defective erythropoiesis through activation of p53 protein family. Blood 2008; 112: 5228-37.
26. Pellagatti A, Marafioti T, Paterson JC, et al. Induction of p53 and up-regulation of the p53 pathway in the human 5q- syndrome. Blood 2010; 115: 2721-3.
27. Dutt S, Narla A, Lin K, et al. Haploinsufficiency for ribosomal protein genes causes selective activation of p53 in human erythroid progenitor cells. Blood 2011; 117: 2567-76.
28. McGowan KA, Pang WW, Bhardwaj R, et al. Reduced ribosomal protein gene dosage and p53 activation in low risk myelodysplastic syndrome. Blood 2011; 118: 3622-33.
29. Virgilio M, Payne E, Narla A, et al. Treatment of Zebrafish Models of Ribosomopathies (Diamond Blackfan Anemia (DBA) and 5q- Syndrome) with L-Leucine Results In An Improvement of Anemia and Developmental Defects: Evidence for a Common Pathway? Blood (ASH Annual Meeting Abstracts) 2010; 116: 195.
30. Starczynowski DT, Kuchenbauer F, Argiropoulos B, et al. Identification of miR-145 and miR-146a as mediators of the 5q- syndrome phenotype. Nat Med 2010; 16: 49-58.
31. Kumar MS, Narla A, Nonami A, et al. Coordinate loss of a microRNA and protein-coding gene cooperate in the pathogenesis of 5q- syndrome. Blood 2011; 118: 4666-73.
32. Dostalova Merkerova M, Krejcik Z, Votavova H, et al. Distinctive microRNA expression profiles in CD34+ bone marrow cells from patients with myelodysplastic syndrome. Eur J Hum Genet 2011; 19: 313-9.
33. Votavova H, Grmanova M, Dostalova Merkerova M, et al. Differential expression of microRNAs in CD34+ cells of 5q- syndrome. J Hematol Oncol 2011; 4: 1.
34. Grisendi S, Bernardi R, Rossi M, et al. Role of nucleophosmin in embryonic development and tumorigenesis. Nature 2005; 437: 147-53.
35. Sportoletti P, Grisendi S, Majid SM, et al. Npm1 is a haploinsufficient suppressor of myeloid and lymphoid malignancies in the mouse. Blood 2008; 111: 3859-62.
36. La Starza R, Matteucci C, Gorello P, et al. NPM1 deletion is associated with gross chromosomal rearrangements in leukemia. PLoS One 2010; 5: e12855.
37. Pellagatti A, Cazzola M, Giagounidis A, et al. Marked downregulation of nucleophosmin-1 is associated with advanced del(5q) myelodysplastic syndrome. Br J Haematol 2011; 155: 272-4.
38. Fidler C, Watkins F, Bowen DT, et al. NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q). Haematologica 2004; 89: 865-6.
39. Jadersten M, Saft L, Smith A, et al. TP53 mutations in low-risk myelodysplastic syndromes with del(5q) predict disease progression. J Clin Oncol 2011; 29: 1971-9.